Form 4: Twist Bioscience COO Sells Shares
Insider Transaction (Form 4)
Patrick John Finn, President and COO of Twist Bioscience Corp, sold 78,355 shares of common stock on August 18, 2026.
Summary
- Option exercise/conversion: acquired 23,355 Common Stock at $67.85 ($1,584,637) on August 18, 2026; holds 293,033 after (Direct).
- Open-market sale: disposed of 33,354 Common Stock at $115.90 ($3,865,695) on August 18, 2026; holds 259,679 after (Direct).
- Open-market sale: disposed of 10,420 Common Stock at $116.82 ($1,217,266) on August 18, 2026; holds 249,259 after (Direct).
- Open-market sale: disposed of 8,868 Common Stock at $117.70 ($1,043,737) on August 18, 2026; holds 240,391 after (Direct).
- Open-market sale: disposed of 4,500 Common Stock at $119.04 ($535,680) on August 18, 2026; holds 235,891 after (Direct).
- Open-market sale: disposed of 12,917 Common Stock at $119.86 ($1,548,206) on August 18, 2026; holds 222,974 after (Direct).
- Open-market sale: disposed of 6,296 Common Stock at $121.01 ($761,860) on August 18, 2026; holds 216,678 after (Direct).
- Open-market sale: disposed of 2,000 Common Stock at $122.58 ($245,162) on August 18, 2026; holds 214,678 after (Direct).
- Option exercise/conversion: disposed of 23,355 Stock Option (right to buy) on August 18, 2026 (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $9,217,607 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Patrick John Finn — Officer (President and COO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-18 | Option exercise/conversion | Common Stock | 23,355 | $68 | $1.6M | 293,033 |
| 2026-08-18 | Open-market sale | Common Stock | 33,354 | $116 | $3.9M | 259,679 |
| 2026-08-18 | Open-market sale | Common Stock | 10,420 | $117 | $1.2M | 249,259 |
| 2026-08-18 | Open-market sale | Common Stock | 8,868 | $118 | $1.0M | 240,391 |
| 2026-08-18 | Open-market sale | Common Stock | 4,500 | $119 | $535.7K | 235,891 |
| 2026-08-18 | Open-market sale | Common Stock | 12,917 | $120 | $1.5M | 222,974 |
| 2026-08-18 | Open-market sale | Common Stock | 6,296 | $121 | $761.9K | 216,678 |
| 2026-08-18 | Open-market sale | Common Stock | 2,000 | $123 | $245.2K | 214,678 |
| 2026-08-18 | Option exercise/conversion | Stock Option (right to buy) | 23,355 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-18 | Option exercise/conversion (23,355 shares) |
| 2026-08-18 | Open-market sale (33,354 shares) |
| 2026-08-18 | Open-market sale (10,420 shares) |
| 2026-08-18 | Open-market sale (8,868 shares) |
| 2026-08-18 | Open-market sale (4,500 shares) |
| 2026-08-18 | Open-market sale (12,917 shares) |
| 2026-08-18 | Open-market sale (6,296 shares) |
| 2026-08-18 | Open-market sale (2,000 shares) |
| 2026-08-18 | Option exercise/conversion (23,355 shares) |
Keywords
insider transaction, Form 4, TWST, Twist Bioscience Corp, bearish, Patrick John Finn
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.